<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03597347</url>
  </required_header>
  <id_info>
    <org_study_id>SAV008-02</org_study_id>
    <nct_id>NCT03597347</nct_id>
  </id_info>
  <brief_title>Trial of Inhaled Molgramostim in Cystic Fibrosis Subjects With Nontuberculous Mycobacterial Infection</brief_title>
  <acronym>ENCORE</acronym>
  <official_title>An Open-label, Non-controlled, Multicenter, Pilot Trial, Using Inhaled Molgramostim in Cystic Fibrosis Subjects With Nontuberculous Mycobacterial (NTM) Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Savara Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Savara Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to evaluate the efficacy of inhaled molgramostim administered open-label to adult&#xD;
      cystic fibrosis (CF) subjects with chronic pulmonary nontuberculous mycobacterial (NTM)&#xD;
      infection, with or without ongoing antimycobacterial guideline based combination therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Screening period will begin up to 10 weeks prior to the Baseline visit for collection of&#xD;
      the sputum sample, but the remainder of the assessments including Safety labs will be&#xD;
      completed within 6 weeks of Baseline, to determine eligibility. Adult participants with a&#xD;
      history of CF and chronic pulmonary NTM infection will be considered for enrollment. Chronic&#xD;
      pulmonary NTM infection will be defined by at least 3 positive NTM cultures (sputum or&#xD;
      broncho-alveolar lavage (BAL)) for the same species/subspecies of mycobacterium avium (MAC)&#xD;
      or mycobacterium abscessus complex (MABSC) within the 2 years prior to screening, with at&#xD;
      least one positive within the past 6 months prior to screening and a minimum of 50% of NTM&#xD;
      cultures positive over the past 2 years. Participants must additionally provide a positive&#xD;
      sputum culture with the same species/subspecies obtained from the central laboratory during&#xD;
      the Screening period to be eligible.&#xD;
&#xD;
      Three groups of participants will be recruited:&#xD;
&#xD;
        -  Group 1: Participants with chronic pulmonary MAC or MABSC infection who have not&#xD;
           consistently achieved negative NTM sputum cultures while currently on a multidrug NTM&#xD;
           guideline-based antimycobacterial regimen, which has been ongoing for at least 9 months&#xD;
           prior to the Baseline visit.&#xD;
&#xD;
        -  Group 2: Participants with chronic pulmonary MAC or MABSC infection who remain sputum&#xD;
           culture positive but have stopped a multidrug NTM guideline-based antimycobacterial&#xD;
           regimen at least 28 days prior to Screening due to lack of response or intolerance.&#xD;
&#xD;
        -  Group 3: Participants with chronic pulmonary MAC or MABSC infection not meeting&#xD;
           recommendations for treatment with a multidrug NTM guideline-based antimycobacterial&#xD;
           regimen based on failure to meet American Thoracic Society/Infectious Diseases Society&#xD;
           of America (ATS/IDSA) criteria for NTM pulmonary disease (i.e. absence of radiologic&#xD;
           findings and clinical symptoms beyond what is expected from underlying CF).&#xD;
&#xD;
      All participants will have Screening, Baseline, Week 1, 2 and followed by monthly Treatment&#xD;
      visits from week 4 during the Treatment period. The Treatment period will be 48 weeks.&#xD;
      Following the End of Treatment (Week 48), subjects will have a Follow-up visit at 4 and 12&#xD;
      weeks, and the End of Study visit 24 weeks after the End of Treatment. At the Baseline visit,&#xD;
      eligible participants will start treatment with inhaled molgramostim.&#xD;
&#xD;
      At each visit any changes in concomitant medication will be recorded. Participants will be&#xD;
      encouraged to contact the clinic between visits if they experience adverse events (AE),&#xD;
      worsening of their condition or have any other concerns. If needed, unscheduled visits will&#xD;
      be conducted at the Investigator's discretion. All participants will be maintained on their&#xD;
      standard CF treatment and medications independent of NTM treatment status.&#xD;
&#xD;
      Treatment with inhaled molgramostim will be given at a dosage of 300 Î¼g once daily for 48&#xD;
      weeks. Dosing will be done in the morning, after completion of the subject's normal airway&#xD;
      clearance routine, where medications should be taken in the following order: bronchodilator,&#xD;
      dornase alfa (Pulmozyme), inhaled antibiotics (e.g. TOBI) and lastly inhaled molgramostim.&#xD;
&#xD;
      Participants on a cyclical on-off anti-Pseudomonal regimen will have their trial visits&#xD;
      (Baseline and subsequent visits in the Treatment Period) scheduled during a week after at&#xD;
      least three weeks off treatment or after at least one week on-treatment of the antibiotic.&#xD;
      Participants on a continuous inhaled regimen, including continuous alternating therapy (CAT),&#xD;
      should have been on a stable regimen for at least 28 days prior to Baseline.&#xD;
&#xD;
      A data review will be conducted after the first 6 participants have completed 12 weeks of&#xD;
      treatment. If safety concerns or poor tolerability are identified in this review, the review&#xD;
      committee may decide on less frequent dosing for subsequent participants in the study.&#xD;
      Additional safety reviews will be conducted at regular intervals thereafter. During the&#xD;
      study, participants in Group 1 will continue use of antimycobacterial treatment, whereas&#xD;
      participants in Groups 2 and 3 will receive inhaled molgramostim as monotherapy for their NTM&#xD;
      infection. For participants in Group 1, the antimycobacterial therapy should preferably not&#xD;
      change during the treatment period except in case of drug toxicity or adverse reactions.&#xD;
      Antibiotics discontinued due to toxicity may be replaced, with drug selection and dose&#xD;
      modification at the discretion of the treating physician. All changes in antimycobacterial&#xD;
      treatment will be recorded, including reasons for each change. In the event the Investigator&#xD;
      has evidence of infection while on treatment which requires more intensive therapy (i.e.&#xD;
      additional antibiotics in Group 1 or addition of antibiotics to Group 2 or 3) the participant&#xD;
      may be allowed to continue after discussion with the Sponsor medical monitor.&#xD;
&#xD;
      No formal sample size calculation was done as this is an initial pilot study. To be able to&#xD;
      assess response in each of the three groups, a minimum of 8 participants with MAC or MABSC&#xD;
      will be enrolled into each of the 3 groups, and a minimum of 30 participants will be enrolled&#xD;
      across all 3 groups. The maximum number of participants enrolled into each group will be 12,&#xD;
      and the maximum number of participants enrolled into the study will be 34.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recruitment for trial stopped early due to limitations from COVID-19, additionally changes in&#xD;
    the standard of care for CF patients during the study period resulted in confounding of the&#xD;
    primary endpoint.&#xD;
  </why_stopped>
  <start_date type="Actual">June 20, 2019</start_date>
  <completion_date type="Actual">October 2, 2020</completion_date>
  <primary_completion_date type="Actual">October 2, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Sputum NTM Culture Conversion to Negative</measure>
    <time_frame>48 weeks</time_frame>
    <description>NTM sputum culture conversion to negative (defined as at least three consecutive negative mycobacterial cultures collected at least 4 weeks apart during the treatment period).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With NTM Sputum Culture Microbiological Cure</measure>
    <time_frame>48 weeks</time_frame>
    <description>NTM sputum culture microbiological cure (defined as multiple consecutive negative but no positive cultures with the causative species after last culture conversion and until the end of treatment (Week 48)).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First NTM Sputum Culture Conversion</measure>
    <time_frame>48 Weeks</time_frame>
    <description>Time to first NTM sputum culture conversion during the treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Sputum Smear Conversion to Negative</measure>
    <time_frame>48 weeks</time_frame>
    <description>Sputum smear conversion to negative (defined as at least three consecutive negative acid-fast bacilli stained sputum smears on microscopy, collected at least 4 weeks apart in subjects who were smear positive at baseline) during the treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Consistent Sputum Smear Conversion to Negative Treatment (Week 48) in Subjects Who Were Smear Positive at Baseline)</measure>
    <time_frame>48 weeks</time_frame>
    <description>Consistent sputum smear conversion to negative (defined as multiple consecutive negative but no positive smears after last smear conversion and until the end of treatment (Week 48) in subjects who were smear positive at baseline).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First NTM Sputum Smear Conversion</measure>
    <time_frame>48 weeks</time_frame>
    <description>Time to first NTM sputum smear conversion during the treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Durable NTM Sputum Microbiological Cure</measure>
    <time_frame>12 weeks after end of treatment</time_frame>
    <description>Durable NTM sputum microbiological cure for the NTM isolate(s) treated without recurrence at Week 12 after end of treatment.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Mycobacterium Infections, Nontuberculous</condition>
  <condition>Cystic Fibrosis (CF)</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with chronic pulmonary MAC or MABSC infection who have not consistently achieved negative NTM sputum cultures while currently on a multidrug NTM guideline-based antimycobacterial regimen, which has been ongoing for at least 9 months prior to the Baseline visit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with chronic pulmonary MAC or MABSC infection who remain sputum culture positive but have stopped a multidrug NTM guideline-based antimycobacterial regimen at least 28 days prior to Screening due to lack of response or intolerance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with chronic pulmonary MAC or MABSC infection not meeting recommendations for treatment with a multidrug NTM guideline-based antimycobacterial regimen based on failure to meet American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) criteria for NTM pulmonary disease (i.e. absence of radiologic findings and clinical symptoms beyond what is expected from underlying CF).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Molgramostim nebulizer solution</intervention_name>
    <description>300 Âµg / dose molgramostim (recombinant human GM-CSF) for inhalation</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <other_name>rhGM-CSF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PARI eFlow nebulizer system</intervention_name>
    <description>PARI eFlow nebulizer system</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent obtained from participant.&#xD;
&#xD;
          2. Confirmed diagnosis of CF according to the Cystic Fibrosis Foundation (CFF) 2017&#xD;
             Consensus Guidelines.&#xD;
&#xD;
          3. History of chronic pulmonary infection with M. avium complex (MAC) or M. abscessus&#xD;
             complex (MABSC) (defined as at least three positive NTM cultures (sputum or BAL for&#xD;
             the same species (MAC) or subspecies (MABSC) within the 2 years prior to the screening&#xD;
             visit, with at least one positive within the past 6 months and a minimum of 50% of NTM&#xD;
             cultures positive over the past 2 years) that does not demonstrate response to current&#xD;
             treatment course based on decreasing NTM burden or frequency of positive cultures, and&#xD;
             in the opinion of the Investigator is unlikely to resolve with current treatment&#xD;
             course.&#xD;
&#xD;
          4. Subject fulfills criteria for inclusion in one of the following groups:&#xD;
&#xD;
             Group 1: Subject with chronic pulmonary MAC or MABSC infection currently on a&#xD;
             multidrug NTM guideline-based antimycobacterial regimen, which has been ongoing for at&#xD;
             least 9 months prior to the Baseline visit.&#xD;
&#xD;
             Group 2: Subject with chronic pulmonary MAC or MABSC infection who has stopped a&#xD;
             multidrug NTM guideline-based antimycobacterial regimen at least 28 days prior to&#xD;
             Screening due to lack of response or intolerance.&#xD;
&#xD;
             Group 3: Subjects with chronic pulmonary MAC or MABSC infection not meeting&#xD;
             recommendations for treatment with a multidrug NTM guideline-based antimycobacterial&#xD;
             regimen based on failure to meet ATS/IDSA criteria for NTM pulmonary disease (i.e.&#xD;
             absence of radiologic findings and clinical symptoms beyond what is expected from&#xD;
             underlying CF).&#xD;
&#xD;
          5. Ability to produce sputum or be willing to undergo an induction protocol that produces&#xD;
             sputum for clinical evaluation.&#xD;
&#xD;
          6. An additional sputum culture performed by the central laboratory, which is positive&#xD;
             for the same species (MAC) or subspecies (MABSC) of NTM as before the trial within 10&#xD;
             weeks of Baseline.&#xD;
&#xD;
          7. CF which in the Investigator's opinion is clinically stable and not expected to&#xD;
             require lung transplantation within the next year.&#xD;
&#xD;
          8. FEV1 â¥ 30% of predicted at screening that is normalized for age, gender, race, and&#xD;
             height, using the Global Lung Function Initiative (GLI) equation.&#xD;
&#xD;
          9. Subjects who are co-infected with a respiratory pathogen, e.g. P. aeruginosa or S.&#xD;
             aureus, must either be stable on a regular suppression antibiotic regimen or must be,&#xD;
             in the opinion of the Investigator, stable despite the lack of such treatment.&#xD;
&#xD;
         10. Female or male â¥18 years of age.&#xD;
&#xD;
         11. If female, subjects who have been post-menopausal for more than 1 year or females of&#xD;
             childbearing potential after a confirmed menstrual period using a highly efficient&#xD;
             method of contraception (i.e. a method with less than 1% failure rate) during and&#xD;
             until 30 days after last dose of trial treatment, having a negative serum pregnancy&#xD;
             test at Screening (Visit 1) and a negative urine pregnancy test at dosing at Baseline&#xD;
             (Visit 2) and must not be lactating.&#xD;
&#xD;
             For purposes of this study, the Sponsor defines &quot;acceptable methods of contraception&quot;&#xD;
             as:&#xD;
&#xD;
               -  Oral birth control pills administered for at least 1 monthly cycle prior to&#xD;
                  administration of the study drug.&#xD;
&#xD;
               -  A synthetic progestin implanted rod (eg, ImplanonÂ®) for at least 1 monthly cycle&#xD;
                  prior to the study drug administration but not beyond the 4th successive year&#xD;
                  following insertion.&#xD;
&#xD;
               -  Intrauterine devices (IUDs), inserted by a qualified clinician for at least 1&#xD;
                  monthly cycle prior to study drug administration.&#xD;
&#xD;
               -  Medroxyprogesterone acetate (eg, Depo-ProveraÂ®) administered for a minimum of 1&#xD;
                  monthly cycle prior to administration of the study drug and continuing through 1&#xD;
                  month following study completion.&#xD;
&#xD;
               -  Hysterectomy or surgical sterilization.&#xD;
&#xD;
               -  Vasectomized partner&#xD;
&#xD;
               -  Abstinence.&#xD;
&#xD;
             Double barrier method (diaphragm with spermicidal gel or condoms with contraceptive&#xD;
             foam) is not considered an acceptable form of contraception.&#xD;
&#xD;
             NOTE: For subjects prescribed Orkambi: Orkambi may substantially decrease hormonal&#xD;
             contraceptive exposure, reducing the effectiveness and increasing the incidence of&#xD;
             menstruation-associated adverse reactions. Hormonal contraceptives, including oral,&#xD;
             injectable, transdermal, and implantable, should not be relied upon as an effective&#xD;
             method of contraception when co-administered with Orkambi.&#xD;
&#xD;
         12. If male, subjects who, if sexually active of reproductive potential and non-sterile&#xD;
             (i.e., male who has not been sterilized by vasectomy for at least 6 months and not&#xD;
             diagnosed with infertility through demonstration of azoospermia in a semen sample&#xD;
             and/or absence of vas deferens through ultrasound) are willing to use a barrier method&#xD;
             of contraception, or their female partner must use an acceptable method of&#xD;
             contraception, during the study and until 30 days after last dose of medication.&#xD;
&#xD;
         13. Willing and able to comply with scheduled visits, treatment plan, laboratory tests,&#xD;
             and other trial procedures specified in the protocol as judged by the Investigator.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Use of non-maintenance antibiotic for a concurrent pulmonary or extrapulmonary&#xD;
             infection within 28 days prior to the Baseline visit.&#xD;
&#xD;
          2. Use of a maintenance antibiotic regimen containing azithromycin for a concurrent&#xD;
             non-NTM pulmonary infection within 28 days prior to the Baseline visit. For subjects&#xD;
             in Group 1, azithromycin is allowed if part of ongoing multidrug NTM guideline-based&#xD;
             antimycobacterial regimen.&#xD;
&#xD;
          3. Prior therapy with inhaled or systemic granulocyte macrophage colony stimulating&#xD;
             factor (GM-CSF).&#xD;
&#xD;
          4. Subjects with hemoptysis of â¥60 mL in a 24-hour period within 4 weeks prior to&#xD;
             Screening.&#xD;
&#xD;
          5. Life expectancy of less than 6 months according to Investigator's judgement.&#xD;
&#xD;
          6. History of, or present, myeloproliferative disease, leukemia or other hematological&#xD;
             malignancy.&#xD;
&#xD;
          7. Active pulmonary malignancy (primary or metastatic); or any malignancy requiring&#xD;
             chemotherapy or radiation therapy within 1 year prior to Screening or anticipated&#xD;
             during the study period.&#xD;
&#xD;
          8. Active autoimmune disorder or other condition requiring therapy associated with&#xD;
             significant immunosuppression, e.g. such as systemic corticosteroids at a dose&#xD;
             equivalent of 10 mg/day or more of prednisolone or other significant immunosuppressant&#xD;
             medications, within 3 months prior to Screening or anticipated during the study&#xD;
             period. Inhaled or topical corticosteroids, or brief courses (&lt;14 days) of systemic&#xD;
             corticosteroids for pulmonary exacerbations or other self-limited conditions are&#xD;
             permitted.&#xD;
&#xD;
          9. Changes in antimicrobial, bronchodilator, anti-inflammatory or corticosteroid&#xD;
             medications, or changes in Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)&#xD;
             modulators, within 28 days prior to the Baseline visit.&#xD;
&#xD;
         10. Pulmonary tuberculosis requiring treatment or treated within 2 years prior to&#xD;
             Screening.&#xD;
&#xD;
         11. History of human immunodeficiency virus (HIV) infection or other disease associated&#xD;
             with significant immunodeficiency.&#xD;
&#xD;
         12. History of lung or other solid organ transplantation or currently on the list to&#xD;
             receive lung or other solid organ transplantation.&#xD;
&#xD;
         13. History of congestive heart failure (CHF) New York Heart Association (NYHA) Class III&#xD;
             or greater in severity.&#xD;
&#xD;
         14. History of cardiovascular ischemic event within 6 months of Baseline.&#xD;
&#xD;
         15. Any change in chronic NTM multi-drug antimycobacterial regimen within 28 days prior to&#xD;
             Screening.&#xD;
&#xD;
         16. Treatment with any investigational medicinal product within 28 days of Screening.&#xD;
&#xD;
         17. Previous experience of severe and unexplained side-effects during aerosol delivery of&#xD;
             any kind of medicinal product.&#xD;
&#xD;
         18. Any other condition that, in the opinion of the Investigator, would preclude informed&#xD;
             consent or assent, make study participation unsafe, complicate interpretation of study&#xD;
             outcome data, or otherwise interfere with achieving the study objectives.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jerry Nick, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Jewish Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Florida Pulmonary Group</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwell Health</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill - UNC Marisco Clinical Research Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27517</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>July 12, 2018</study_first_submitted>
  <study_first_submitted_qc>July 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2018</study_first_posted>
  <results_first_submitted>September 13, 2021</results_first_submitted>
  <results_first_submitted_qc>September 13, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 11, 2021</results_first_posted>
  <last_update_submitted>October 10, 2021</last_update_submitted>
  <last_update_submitted_qc>October 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nontuberculosis mycobacterial infection</keyword>
  <keyword>Cystic fibrosis</keyword>
  <keyword>M. avium complex</keyword>
  <keyword>M. abscessus complex</keyword>
  <keyword>Mycobacterium Infections, Nontuberculous</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Mycobacterium Infections</mesh_term>
    <mesh_term>Mycobacterium Infections, Nontuberculous</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Molgramostim</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 12, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/47/NCT03597347/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 9, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/47/NCT03597347/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>6 sites in US participated in the study. The first participant was enrolled on 20 June 2019 and last participant completed the study on 2 October 2020, the same date the study was terminated.</recruitment_details>
      <pre_assignment_details>A total of 28 subjects were screened for the trial. Fourteen subjects were screening failures.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Not Consistently NTM Sputum Negative</title>
          <description>Participants with chronic pulmonary MAC or MABSC infection who have not consistently achieved negative NTM sputum cultures while currently on a multidrug NTM guideline-based antimycobacterial regimen, which has been ongoing for at least 9 months prior to the Baseline visit.&#xD;
Molgramostim nebulizer solution: 300 Âµg / dose molgramostim (recombinant human GM-CSF) for inhalation&#xD;
PARI eFlow nebulizer system: PARI eFlow nebulizer system</description>
        </group>
        <group group_id="P2">
          <title>NTM Sputum Positive</title>
          <description>Participants with chronic pulmonary MAC or MABSC infection who remain sputum culture positive but have stopped a multidrug NTM guideline-based antimycobacterial regimen at least 28 days prior to Screening due to lack of response or intolerance.&#xD;
Molgramostim nebulizer solution: 300 Âµg / dose molgramostim (recombinant human GM-CSF) for inhalation&#xD;
PARI eFlow nebulizer system: PARI eFlow nebulizer system</description>
        </group>
        <group group_id="P3">
          <title>Did Not Meet Recommendations for Treatment With a Multidrug NTM Antimycobacterial Treatment</title>
          <description>Participants with chronic pulmonary MAC or MABSC infection not meeting recommendations for treatment with a multidrug NTM guideline-based antimycobacterial regimen based on failure to meet American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) criteria for NTM pulmonary disease (i.e. absence of radiologic findings and clinical symptoms beyond what is expected from underlying CF).&#xD;
Molgramostim nebulizer solution: 300 Âµg / dose molgramostim (recombinant human GM-CSF) for inhalation&#xD;
PARI eFlow nebulizer system: PARI eFlow nebulizer system</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal due to Covid-19</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor decision to terminate study</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1</title>
          <description>Participants with chronic pulmonary MAC or MABSC infection who have not consistently achieved negative NTM sputum cultures while currently on a multidrug NTM guideline-based antimycobacterial regimen, which has been ongoing for at least 9 months prior to the Baseline visit.&#xD;
Molgramostim nebulizer solution: 300 Âµg / dose molgramostim (recombinant human GM-CSF) for inhalation&#xD;
PARI eFlow nebulizer system: PARI eFlow nebulizer system</description>
        </group>
        <group group_id="B2">
          <title>Group 2</title>
          <description>Participants with chronic pulmonary MAC or MABSC infection who remain sputum culture positive but have stopped a multidrug NTM guideline-based antimycobacterial regimen at least 28 days prior to Screening due to lack of response or intolerance.&#xD;
Molgramostim nebulizer solution: 300 Âµg / dose molgramostim (recombinant human GM-CSF) for inhalation&#xD;
PARI eFlow nebulizer system: PARI eFlow nebulizer system</description>
        </group>
        <group group_id="B3">
          <title>Group 3</title>
          <description>Participants with chronic pulmonary MAC or MABSC infection not meeting recommendations for treatment with a multidrug NTM guideline-based antimycobacterial regimen based on failure to meet American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) criteria for NTM pulmonary disease (i.e. absence of radiologic findings and clinical symptoms beyond what is expected from underlying CF).&#xD;
Molgramostim nebulizer solution: 300 Âµg / dose molgramostim (recombinant human GM-CSF) for inhalation&#xD;
PARI eFlow nebulizer system: PARI eFlow nebulizer system</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.0" spread="11.78"/>
                    <measurement group_id="B2" value="46.3" spread="20.03"/>
                    <measurement group_id="B3" value="38.8" spread="12.28"/>
                    <measurement group_id="B4" value="35.5" spread="14.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Causative species/ subspecies</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Mycobacterium abscessus ss abscessus</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mycobacterium abscessus ss massiliense</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mycobacterium avium</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Sputum NTM Culture Conversion to Negative</title>
        <description>NTM sputum culture conversion to negative (defined as at least three consecutive negative mycobacterial cultures collected at least 4 weeks apart during the treatment period).</description>
        <time_frame>48 weeks</time_frame>
        <population>Safety analysis set (participants who received at least one dose of trial treatment).</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Participants with chronic pulmonary MAC or MABSC infection who have not consistently achieved negative NTM sputum cultures while currently on a multidrug NTM guideline-based antimycobacterial regimen, which has been ongoing for at least 9 months prior to the Baseline visit.&#xD;
Molgramostim nebulizer solution: 300 Âµg / dose molgramostim (recombinant human GM-CSF) for inhalation&#xD;
PARI eFlow nebulizer system: PARI eFlow nebulizer system</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Participants with chronic pulmonary MAC or MABSC infection who remain sputum culture positive but have stopped a multidrug NTM guideline-based antimycobacterial regimen at least 28 days prior to Screening due to lack of response or intolerance.&#xD;
Molgramostim nebulizer solution: 300 Âµg / dose molgramostim (recombinant human GM-CSF) for inhalation&#xD;
PARI eFlow nebulizer system: PARI eFlow nebulizer system</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Participants with chronic pulmonary MAC or MABSC infection not meeting recommendations for treatment with a multidrug NTM guideline-based antimycobacterial regimen based on failure to meet American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) criteria for NTM pulmonary disease (i.e. absence of radiologic findings and clinical symptoms beyond what is expected from underlying CF).&#xD;
Molgramostim nebulizer solution: 300 Âµg / dose molgramostim (recombinant human GM-CSF) for inhalation&#xD;
PARI eFlow nebulizer system: PARI eFlow nebulizer system</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Sputum NTM Culture Conversion to Negative</title>
          <description>NTM sputum culture conversion to negative (defined as at least three consecutive negative mycobacterial cultures collected at least 4 weeks apart during the treatment period).</description>
          <population>Safety analysis set (participants who received at least one dose of trial treatment).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With NTM Sputum Culture Microbiological Cure</title>
        <description>NTM sputum culture microbiological cure (defined as multiple consecutive negative but no positive cultures with the causative species after last culture conversion and until the end of treatment (Week 48)).</description>
        <time_frame>48 weeks</time_frame>
        <population>Safety analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Participants with chronic pulmonary MAC or MABSC infection who have not consistently achieved negative NTM sputum cultures while currently on a multidrug NTM guideline-based antimycobacterial regimen, which has been ongoing for at least 9 months prior to the Baseline visit.&#xD;
Molgramostim nebulizer solution: 300 Âµg / dose molgramostim (recombinant human GM-CSF) for inhalation&#xD;
PARI eFlow nebulizer system: PARI eFlow nebulizer system</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Participants with chronic pulmonary MAC or MABSC infection who remain sputum culture positive but have stopped a multidrug NTM guideline-based antimycobacterial regimen at least 28 days prior to Screening due to lack of response or intolerance.&#xD;
Molgramostim nebulizer solution: 300 Âµg / dose molgramostim (recombinant human GM-CSF) for inhalation&#xD;
PARI eFlow nebulizer system: PARI eFlow nebulizer system</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Participants with chronic pulmonary MAC or MABSC infection not meeting recommendations for treatment with a multidrug NTM guideline-based antimycobacterial regimen based on failure to meet American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) criteria for NTM pulmonary disease (i.e. absence of radiologic findings and clinical symptoms beyond what is expected from underlying CF).&#xD;
Molgramostim nebulizer solution: 300 Âµg / dose molgramostim (recombinant human GM-CSF) for inhalation&#xD;
PARI eFlow nebulizer system: PARI eFlow nebulizer system</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With NTM Sputum Culture Microbiological Cure</title>
          <description>NTM sputum culture microbiological cure (defined as multiple consecutive negative but no positive cultures with the causative species after last culture conversion and until the end of treatment (Week 48)).</description>
          <population>Safety analysis set.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First NTM Sputum Culture Conversion</title>
        <description>Time to first NTM sputum culture conversion during the treatment period.</description>
        <time_frame>48 Weeks</time_frame>
        <population>Only participants who had NTM sputum culture conversion during the treatment period were analyzed. The mean survival time and its standard error of the mean were underestimated because the largest observation was censored and the estimation was restricted to the largest event time.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Participants with chronic pulmonary MAC or MABSC infection who have not consistently achieved negative NTM sputum cultures while currently on a multidrug NTM guideline-based antimycobacterial regimen, which has been ongoing for at least 9 months prior to the Baseline visit.&#xD;
Molgramostim nebulizer solution: 300 Âµg / dose molgramostim (recombinant human GM-CSF) for inhalation&#xD;
PARI eFlow nebulizer system: PARI eFlow nebulizer system</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Participants with chronic pulmonary MAC or MABSC infection who remain sputum culture positive but have stopped a multidrug NTM guideline-based antimycobacterial regimen at least 28 days prior to Screening due to lack of response or intolerance.&#xD;
Molgramostim nebulizer solution: 300 Âµg / dose molgramostim (recombinant human GM-CSF) for inhalation&#xD;
PARI eFlow nebulizer system: PARI eFlow nebulizer system</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Participants with chronic pulmonary MAC or MABSC infection not meeting recommendations for treatment with a multidrug NTM guideline-based antimycobacterial regimen based on failure to meet American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) criteria for NTM pulmonary disease (i.e. absence of radiologic findings and clinical symptoms beyond what is expected from underlying CF).&#xD;
Molgramostim nebulizer solution: 300 Âµg / dose molgramostim (recombinant human GM-CSF) for inhalation&#xD;
PARI eFlow nebulizer system: PARI eFlow nebulizer system</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First NTM Sputum Culture Conversion</title>
          <description>Time to first NTM sputum culture conversion during the treatment period.</description>
          <population>Only participants who had NTM sputum culture conversion during the treatment period were analyzed. The mean survival time and its standard error of the mean were underestimated because the largest observation was censored and the estimation was restricted to the largest event time.</population>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.21" spread="1.991"/>
                    <measurement group_id="O2" value="8.57"/>
                    <measurement group_id="O3" value="21.54" spread="1.933"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Sputum Smear Conversion to Negative</title>
        <description>Sputum smear conversion to negative (defined as at least three consecutive negative acid-fast bacilli stained sputum smears on microscopy, collected at least 4 weeks apart in subjects who were smear positive at baseline) during the treatment period.</description>
        <time_frame>48 weeks</time_frame>
        <population>Safety analysis set. Only participants who had positive smear at baseline were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Participants with chronic pulmonary MAC or MABSC infection who have not consistently achieved negative NTM sputum cultures while currently on a multidrug NTM guideline-based antimycobacterial regimen, which has been ongoing for at least 9 months prior to the Baseline visit.&#xD;
Molgramostim nebulizer solution: 300 Âµg / dose molgramostim (recombinant human GM-CSF) for inhalation&#xD;
PARI eFlow nebulizer system: PARI eFlow nebulizer system</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Participants with chronic pulmonary MAC or MABSC infection who remain sputum culture positive but have stopped a multidrug NTM guideline-based antimycobacterial regimen at least 28 days prior to Screening due to lack of response or intolerance.&#xD;
Molgramostim nebulizer solution: 300 Âµg / dose molgramostim (recombinant human GM-CSF) for inhalation&#xD;
PARI eFlow nebulizer system: PARI eFlow nebulizer system</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Participants with chronic pulmonary MAC or MABSC infection not meeting recommendations for treatment with a multidrug NTM guideline-based antimycobacterial regimen based on failure to meet American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) criteria for NTM pulmonary disease (i.e. absence of radiologic findings and clinical symptoms beyond what is expected from underlying CF).&#xD;
Molgramostim nebulizer solution: 300 Âµg / dose molgramostim (recombinant human GM-CSF) for inhalation&#xD;
PARI eFlow nebulizer system: PARI eFlow nebulizer system</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Sputum Smear Conversion to Negative</title>
          <description>Sputum smear conversion to negative (defined as at least three consecutive negative acid-fast bacilli stained sputum smears on microscopy, collected at least 4 weeks apart in subjects who were smear positive at baseline) during the treatment period.</description>
          <population>Safety analysis set. Only participants who had positive smear at baseline were analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Consistent Sputum Smear Conversion to Negative Treatment (Week 48) in Subjects Who Were Smear Positive at Baseline)</title>
        <description>Consistent sputum smear conversion to negative (defined as multiple consecutive negative but no positive smears after last smear conversion and until the end of treatment (Week 48) in subjects who were smear positive at baseline).</description>
        <time_frame>48 weeks</time_frame>
        <population>Safety analysis set. Only participants who had positive smear at baseline were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Participants with chronic pulmonary MAC or MABSC infection who have not consistently achieved negative NTM sputum cultures while currently on a multidrug NTM guideline-based antimycobacterial regimen, which has been ongoing for at least 9 months prior to the Baseline visit.&#xD;
Molgramostim nebulizer solution: 300 Âµg / dose molgramostim (recombinant human GM-CSF) for inhalation&#xD;
PARI eFlow nebulizer system: PARI eFlow nebulizer system</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Participants with chronic pulmonary MAC or MABSC infection who remain sputum culture positive but have stopped a multidrug NTM guideline-based antimycobacterial regimen at least 28 days prior to Screening due to lack of response or intolerance.&#xD;
Molgramostim nebulizer solution: 300 Âµg / dose molgramostim (recombinant human GM-CSF) for inhalation&#xD;
PARI eFlow nebulizer system: PARI eFlow nebulizer system</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Participants with chronic pulmonary MAC or MABSC infection not meeting recommendations for treatment with a multidrug NTM guideline-based antimycobacterial regimen based on failure to meet American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) criteria for NTM pulmonary disease (i.e. absence of radiologic findings and clinical symptoms beyond what is expected from underlying CF).&#xD;
Molgramostim nebulizer solution: 300 Âµg / dose molgramostim (recombinant human GM-CSF) for inhalation&#xD;
PARI eFlow nebulizer system: PARI eFlow nebulizer system</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Consistent Sputum Smear Conversion to Negative Treatment (Week 48) in Subjects Who Were Smear Positive at Baseline)</title>
          <description>Consistent sputum smear conversion to negative (defined as multiple consecutive negative but no positive smears after last smear conversion and until the end of treatment (Week 48) in subjects who were smear positive at baseline).</description>
          <population>Safety analysis set. Only participants who had positive smear at baseline were analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First NTM Sputum Smear Conversion</title>
        <description>Time to first NTM sputum smear conversion during the treatment period.</description>
        <time_frame>48 weeks</time_frame>
        <population>Safety analysis set. Only participants who had positive smear at baseline were analyzed. The mean survival time and its standard error were underestimated because the largest observation was censored and the estimation was restricted to the largest event time.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Participants with chronic pulmonary MAC or MABSC infection who have not consistently achieved negative NTM sputum cultures while currently on a multidrug NTM guideline-based antimycobacterial regimen, which has been ongoing for at least 9 months prior to the Baseline visit.&#xD;
Molgramostim nebulizer solution: 300 Âµg / dose molgramostim (recombinant human GM-CSF) for inhalation&#xD;
PARI eFlow nebulizer system: PARI eFlow nebulizer system</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Participants with chronic pulmonary MAC or MABSC infection who remain sputum culture positive but have stopped a multidrug NTM guideline-based antimycobacterial regimen at least 28 days prior to Screening due to lack of response or intolerance.&#xD;
Molgramostim nebulizer solution: 300 Âµg / dose molgramostim (recombinant human GM-CSF) for inhalation&#xD;
PARI eFlow nebulizer system: PARI eFlow nebulizer system</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Participants with chronic pulmonary MAC or MABSC infection not meeting recommendations for treatment with a multidrug NTM guideline-based antimycobacterial regimen based on failure to meet American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) criteria for NTM pulmonary disease (i.e. absence of radiologic findings and clinical symptoms beyond what is expected from underlying CF).&#xD;
Molgramostim nebulizer solution: 300 Âµg / dose molgramostim (recombinant human GM-CSF) for inhalation&#xD;
PARI eFlow nebulizer system: PARI eFlow nebulizer system</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First NTM Sputum Smear Conversion</title>
          <description>Time to first NTM sputum smear conversion during the treatment period.</description>
          <population>Safety analysis set. Only participants who had positive smear at baseline were analyzed. The mean survival time and its standard error were underestimated because the largest observation was censored and the estimation was restricted to the largest event time.</population>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.55" spread="2.084"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Durable NTM Sputum Microbiological Cure</title>
        <description>Durable NTM sputum microbiological cure for the NTM isolate(s) treated without recurrence at Week 12 after end of treatment.</description>
        <time_frame>12 weeks after end of treatment</time_frame>
        <population>Safety analysis set. Only participants who had positive smear at baseline were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Participants with chronic pulmonary MAC or MABSC infection who have not consistently achieved negative NTM sputum cultures while currently on a multidrug NTM guideline-based antimycobacterial regimen, which has been ongoing for at least 9 months prior to the Baseline visit.&#xD;
Molgramostim nebulizer solution: 300 Âµg / dose molgramostim (recombinant human GM-CSF) for inhalation&#xD;
PARI eFlow nebulizer system: PARI eFlow nebulizer system</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Participants with chronic pulmonary MAC or MABSC infection who remain sputum culture positive but have stopped a multidrug NTM guideline-based antimycobacterial regimen at least 28 days prior to Screening due to lack of response or intolerance.&#xD;
Molgramostim nebulizer solution: 300 Âµg / dose molgramostim (recombinant human GM-CSF) for inhalation&#xD;
PARI eFlow nebulizer system: PARI eFlow nebulizer system</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Participants with chronic pulmonary MAC or MABSC infection not meeting recommendations for treatment with a multidrug NTM guideline-based antimycobacterial regimen based on failure to meet American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) criteria for NTM pulmonary disease (i.e. absence of radiologic findings and clinical symptoms beyond what is expected from underlying CF).&#xD;
Molgramostim nebulizer solution: 300 Âµg / dose molgramostim (recombinant human GM-CSF) for inhalation&#xD;
PARI eFlow nebulizer system: PARI eFlow nebulizer system</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Durable NTM Sputum Microbiological Cure</title>
          <description>Durable NTM sputum microbiological cure for the NTM isolate(s) treated without recurrence at Week 12 after end of treatment.</description>
          <population>Safety analysis set. Only participants who had positive smear at baseline were analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-emergent adverse events (AEs) were assessed on or after the first dose of trial drug to 28 days after last dose.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group 1</title>
          <description>Participants with chronic pulmonary MAC or MABSC infection who have not consistently achieved negative NTM sputum cultures while currently on a multidrug NTM guideline-based antimycobacterial regimen, which has been ongoing for at least 9 months prior to the Baseline visit.&#xD;
Molgramostim nebulizer solution: 300 Âµg / dose molgramostim (recombinant human GM-CSF) for inhalation&#xD;
PARI eFlow nebulizer system: PARI eFlow nebulizer system</description>
        </group>
        <group group_id="E2">
          <title>Group 2</title>
          <description>Participants with chronic pulmonary MAC or MABSC infection who remain sputum culture positive but have stopped a multidrug NTM guideline-based antimycobacterial regimen at least 28 days prior to Screening due to lack of response or intolerance.&#xD;
Molgramostim nebulizer solution: 300 Âµg / dose molgramostim (recombinant human GM-CSF) for inhalation&#xD;
PARI eFlow nebulizer system: PARI eFlow nebulizer system</description>
        </group>
        <group group_id="E3">
          <title>Group 3</title>
          <description>Participants with chronic pulmonary MAC or MABSC infection not meeting recommendations for treatment with a multidrug NTM guideline-based antimycobacterial regimen based on failure to meet American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) criteria for NTM pulmonary disease (i.e. absence of radiologic findings and clinical symptoms beyond what is expected from underlying CF).&#xD;
Molgramostim nebulizer solution: 300 Âµg / dose molgramostim (recombinant human GM-CSF) for inhalation&#xD;
PARI eFlow nebulizer system: PARI eFlow nebulizer system</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 22.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infective pulmonary exacerbation of cystic fibrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 22.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Parotid duct obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Complication associated with device</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Feeling abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infective pulmonary exacerbation of cystic fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Oral fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Albumin urine present</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Blood chloride decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Blood magnesium decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Glucose urine present</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Specific gravity urine decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Urine ketone body present</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Insomina</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Mania</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Sputum increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Increased bronchial secretion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nasal crusting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Upper-airway cough syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Sputum discoloured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Skin fissures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to the early termination of the study, some specified endpoints had insufficient data to be analyzed:&#xD;
* Durable NTM sputum smear conversion to negative without subsequent positive smears at Week 12 after End of Treatment (EOT).&#xD;
Change from Baseline to EOT and Week 12 after EOT in:&#xD;
semi-quantitative grade of number of NTM on microscopy of AFB stained sputum smears&#xD;
FEV1 (percent predicted)&#xD;
respiratory domain score assessed by CFQ-R&#xD;
body mass index</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dhaval Desai, VP Head of Clinical Development</name_or_title>
      <organization>Savara Inc</organization>
      <phone>+1 302-442-2309</phone>
      <email>dhaval.desai@savarapharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

